ArticleJournal of hepatocellular carcinoma2022
Dynamic Lymphocyte Changes Following Transarterial Radioembolization: Association with Normal Liver Dose and Effect on Overall Survival.
Article in Journal of hepatocellular carcinoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.Discover oncology · 2026Article
- Radiation-induced lymphopenia is associated with survival in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.JHEP reports : innovation in hepatology · 2026Article
- Review
- Dynamic Neutrophil-to-Lymphocyte Ratio at 3-4 weeks of Intensity-Modulated Radiotherapy Combined with Normal Liver Volume Predicts Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma: A Retrospective Study.Journal of inflammation research · 2025Article
- Interventional oncology and immunotherapy: current status and future perspectives.Frontiers in immunology · 2025Review
- Progressive Multifocal Leukoencephalopathy in a Patient With Cirrhosis and Hepatocellular Carcinoma.The Neurohospitalist · 2024Article
- Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.Seminars in interventional radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the dynamic changes of lymphocytes following transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) and their relationship to normal liver dose (NLD). MATERIALS AND
methodsA total of 93 patients who underwent 102 treatments were retrospectively reviewed. Absolute lymphocyte counts pretreatment and at 1, 3, 6, and 12 months were evaluated. Kaplan-Meier, Spearman correlation, receiver operating characteristic (ROC) curve, and area under the curve (AUC) analyses were performed.
resultsThe mean absolute lymphocyte count at baseline was 1.25 ± 0.79 10
conclusionNLD may correlate with lymphocyte depression at 1 and 3 months and lymphopenia may portend a worse overall survival in the post treatment setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.